FDA Hydroquinone Proposal Should Prompt Industry Studies – Dermatologists
This article was originally published in The Tan Sheet
Executive Summary
Dermatologists concerned about losing over-the-counter access to skin bleaching products formulated with hydroquinone - as proposed by FDA - are counting on industry to submit compelling safety data
You may also be interested in...
Proposed Hydroquinone Ban Criticized In Literature Review
Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology
FDA Pushes For Prescription-Only Sale Of Skin-Bleaching Products
FDA is proposing a rule that classifies all over-the-counter skin-bleaching products as drugs requiring an approved new drug application, the agency announced in a notice of proposed rulemaking published in an Aug. 29 Federal Register notice
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC